Ultrasound Training Escalates in the United States

Save

A recent report cites the frequency of musculoskeletal (MSK) ultrasound (US) education in US residency and fellowship training programs.

Lupus Flares After Renal Transplant

Save

Whether lupus activity is ameliorated by end-stage renal disease (ESRD) or transplantation has been debated.

Smoking and Age Linked to Development of Inflammatory Arthritis

Save

A prospective cohort of RA first-degree relatives were prospectively studied for genetic and environmental factors (smoking, body mass index, education, and parity) and RA-related autoantibodies that may influence future development of inflammatory joint symptoms over a 2 year&nbsp

Prescribers More Likely to Escalate to Biologics than Triple DMARD Therapy

Save

The paradigm for DMARD use in rheumatoid arthritis (RA) begins with DMARD monotherapy and then escalates to combination therapy with either DMARDs or a combination of conventional DMARD plus a biologic DMARD (bDMARD).

RWCS 2016 – OA/OP, Gout, Sarcoid & JIA Reviewed

Save

Recent Developments in Osteoarthritis, Osteoporosis and Gout

RWCS 2016 – Rheumatoid Review, Psoriatic Arthritis and Medical Marijuana

Save

The Rheumatology Winter Clinical Symposia launched its 9th annual conference yesterday in Maui. Highlights of this meeting will be covered by RheumNow from Wednesday 2/10 till Saturday 2/13.

Rheumatoid Arthritis Year in Review

What To Do After Teriparatide?

Save

Once the clock runs out on teriparatide (TPTD or Forteo), what is the next best option?

Rheumatoid Modern Management is Better but More Costly

Save

The mantra of rheumatologists worldwide is to treat rheumatoid arthritis (RA) earlier and more aggressively. While referral of early RA patients has improved, there is little data demonstrating that more aggressive treatment works or is cost effective.

FDA Advisory Arthritis Committee Votes to Approve the CT-P13 (infliximab) Biosimilar

Save

On Tuesday February 9th Celltrion presented its biosimilar developmental data to the FDA as they sought approval for their CT-P13 (called Inflectra), a biosimilar of infliximab (Remicade).

FDA Reviews Celltrion's Remicade Biosimilar Today

Save

The arthritis advisory committee of the Food and Drug Administration (FDA) is scheduled to meet today, February 9th to review the efficacy and safety of Celltrion's biosimilar form of infliximab (Remicade) that is currently marketed in other countries.

Parenteral Methotrexate Intolerance is High in Juvenile Idiopathic Arthritis

Save

Juvenile idiopathic arthritis (JIA) is commonly managed with methotrexate (MTX), with many pediatric rheumatologists preferring to use parenteral MTX for compliance and absorption reasons.

Racial Disparity in Cardiovascular Risks with Connective Tissue Disorders

Save

Cardiovascular events account for significant morbidity and mortality in patients with rheumatoid arthritis (RA) and other connnective tissue disorders (CTD). Investigators analyzed health records from a large U.S.

Should You Avoid Pneumococcal Vaccine in CAPS and Behcet's Patients

Save

Althought EULAR currently recommends the pneumococcal vaccine be given to patients with inflammatory rheumatic diseases and the Centers for Disease Control and Prevention (CDC) recommends the vaccine in patients treated with immunosuppressive drugs, a recent brief report suggests it be

Increased Congenital Anomalies in Children from Women with a Juvenile Arthritis History

Save

A Quebec administrative claims analysis examined the birth outcomes of women with a history of juvenile idiopathic arthritis (JIA) who subsequently had a first-time birth (between 1983-2010).

Rheumatoid Arthritis, TNF inhibitors and the Risk of Skin Cancer

Save

Rheumatoid arthritis (RA) patients are said to have a neutral risk for neoplasia, but this is because they have a lower risk of colon cancer and breast cancer but a higher risk of lung cancer, lymphoma and skin cancers.

High 14-3-3η Levels Have Predictive Value in Early Inflammatory Arthritis

Save

14-3-3η is a new serum assay that has utility in diagnosing and treating patients with rheumatoid arthritis (RA) and early inflammatory arthritis (EIA).

Comorbidities Start Early in Rheumatoid Arthritis

Save

A Northern Sweden early rheumatoid arthritis (RA) cohort of 950 patients was enrolled starting in 1995. A validated questionnaire at RA onset (T0) and after 5 years (T5) after enrollment. Currently, 726 of these have had RA for ≥5 years.

No Significant Increased Risk with TNF Inhibitors During Pregnancy

Save

A population-based study of 1,272,424 live-born infants from Denmark and Sweden examined the prevalence of birth defects among infants born to 683 women with chronic inflammatory disease (inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or psoriasis)

Ultrasound Predicts Inflammatory Arthritis in CCP+ Persons Without Synovitis

Save

A prospective study of 136 people who were CCP+, but who had no clinical evidence of synovitis, examined what factors may predict future development of inflammatory arthritis.

Updated RA Treat-to-Target International Recommendations

Save

In 2010, Smolen and a group of international rheumatologists developed a series of recommendations addressing the concept of treat-to-target (T2T) in the management of rheumatoid arthritis (RA).